Received Jul 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | IM |
received his first dose in February of 2020 and his 2nd in May of 2025; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in February 2020). In MAY-2025, the patient received the 2nd dose of Shingrix (intramuscular). In MAY-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received his first dose in February of 2020 and his 2nd in May of 2025). In MAY-2025, the outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 22-JUL-2025 The nurse reported that the patient received his first dose of Shingrix in February of 2020 and his 2nd dose in May of 2025. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.